Company intelligence / Profile preview

NeurAxis

Carmel, Indiana, United Statesneuraxis.com ↗

Ownership: Public · NRXS
Employees: ~21
Development stage: Commercial

Overview

NeurAxis has achieved FDA clearance for its IB-Stim device to treat functional abdominal pain associated with IBS and functional dyspepsia in pediatric patients aged 8–21. The company’s clinical evidence base includes at least 16 peer-reviewed publications from US children’s hospitals. Commercialization is underway for both IB-Stim and the newly cleared RED product for chronic constipation assessment. Revenue growth has been strong, supported by expanded insurance coverage and new CPT coding.

Therapeutic areas: Gastroenterology
Modalities: DeviceNeuromodulation therapy
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

IB-Stim

Commercial

Indications: Functional abdominal pain, Irritable bowel syndrome

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $73.7M
Total revenue: $1.9M
Enterprise value: $65.7M

Beyond the preview

Go deeper on NeurAxis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeurAxis.

Explore the full profile